EBITDA grew 10.5% year-on-year to ₹162.7 crore from ₹147.2 crore in the corresponding quarter last year. However, EBITDA margin slipped marginally to 13.8% from 14%, indicating some pressure from input costs and operating expenses.
The March-quarter performance marked an improvement from the December quarter, when the company had reported a 32.4% decline in profit amid softer operating performance and margin contraction. In Q3FY26, net profit had fallen to ₹47 crore, while EBITDA margin had narrowed to 12% from 13% a year earlier.
The board recommended a final dividend of ₹2.50 per equity share of Re 1 each for FY26, subject to shareholder approval at the upcoming annual general meeting. The company has fixed July 24, 2026, as the record date for determining shareholder eligibility for the dividend payout.Earlier in February, the company had also announced an interim dividend of ₹2.50 per share for FY26.
Also Read: Solarworld Energy Q4 Results: Profit surges as revenue more than triples
Despite the earnings improvement, shares of Jubilant Ingrevia were under pressure on Tuesday. The stock was trading 6% lower at ₹688.00 on the NSE in afternoon trade.
Jubilant Ingrevia manufactures speciality chemicals, nutrition and health solutions, and life science ingredients catering to pharmaceuticals, agrochemicals, consumer products and industrial applications.
